← Viatris Inc
| Annual Trend | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Depreciation and amortization | $2.1b | $2.0b | $2.2b | $4.5b | $3.0b | $2.7b | $2.9b | $2.8b | |
| Deferred income tax benefit | ($264.3m) | ($192.6m) | ($213.2m) | $675.7m | ($25.9m) | ($387.1m) | ($767.6m) | ($476.5m) | |
| Share-based compensation expense | ($3.3m) | $56.8m | $79.2m | $111.2m | $116.4m | $180.7m | $146.1m | $177.7m | |
| Impairment of goodwill | — | — | — | — | — | $580.1m | $321.0m | $2.9b | |
| Net (loss) earnings | $352.5m | $16.8m | ($669.9m) | ($1.3b) | $2.1b | $54.7m | ($634.2m) | ($3.5b) | |
| Litigation settlements and other contingencies, net | ($31.6m) | ($11.5m) | $101.1m | $323.7m | ($1.7m) | $86.8m | $274.5m | ($40.2m) | |
| Loss on disposal of business | — | — | $0 | $0 | ($1.8b) | $239.9m | $399.5m | $101.0m | |
| Acquired IPR&D | — | — | — | — | $46.4m | $100.4m | $12.3m | $50.8m | |
| Other non-cash items | $286.1m | $360.6m | $366.4m | $411.8m | $434.3m | $595.4m | $297.7m | $969.3m | |
| Accounts receivable | $340.1m | ($20.0m) | $78.7m | $59.3m | ($240.3m) | $78.6m | $300.1m | $334.6m | |
| Inventories | ($547.6m) | ($512.9m) | ($741.9m) | ($427.6m) | ($259.5m) | ($613.3m) | ($723.4m) | ($106.4m) | |
| Trade accounts payable | $220.3m | ($96.3m) | ($82.7m) | ($70.4m) | $170.2m | $314.7m | $36.0m | ($168.0m) | |
| Income taxes | $228.6m | $0 | $324.4m | $641.7m | $735.2m | $570.9m | $514.0m | ($112.9m) | |
| Other operating assets and liabilities, net | ($177.9m) | $63.5m | $46.0m | ($666.5m) | ($618.3m) | ($414.6m) | ($150.6m) | ($633.7m) | |
| Cash paid for acquisitions, net of cash acquired | ($65.9m) | ($148.7m) | $415.8m | $277.0m | $0 | ($667.7m) | ($350.0m) | $0 | |
| Payments for product rights and other, net | ($943.5m) | ($192.8m) | ($438.2m) | ($52.2m) | ($37.0m) | ($97.5m) | ($20.8m) | ($35.5m) | |
| Purchases of IPR&D | — | — | — | — | ($46.4m) | ($100.4m) | ($12.3m) | ($50.8m) | |
| Proceeds from sale of assets and subsidiaries | $29.3m | $28.0m | $20.0m | $96.7m | $1.9b | $364.1m | $2.5b | $2.5m | |
| Purchase of marketable securities | ($63.4m) | ($25.8m) | ($104.8m) | ($30.2m) | ($30.2m) | ($26.3m) | ($26.0m) | ($23.9m) | |
| Proceeds from the sale of marketable securities | $85.2m | $27.1m | $47.0m | $29.8m | $29.9m | $26.3m | $26.0m | $23.9m | |
| Payments of financing fees | ($21.4m) | ($3.0m) | ($2.0m) | ($7.0m) | ($1.9m) | ($500k) | ($4.8m) | ($1.5m) | |
| Change in short-term borrowings, net | ($44.4m) | ($1.8m) | $1.1b | $392.1m | ($1.5b) | $300k | $0 | $200k | |
| Purchase of ordinary shares | ($432.0m) | $0 | $0 | $0 | $0 | ($250.0m) | ($250.0m) | ($500.5m) | |
| Contingent consideration payments | ($11.9m) | ($60.3m) | ($48.5m) | ($28.6m) | ($18.9m) | ($8.4m) | ($31.5m) | ($13.1m) | |
| Non-contingent payments for product rights | $0 | $0 | ($143.3m) | ($456.0m) | $0 | ($9.7m) | $0 | $0 | |
| Other items, net | ($1.0m) | ($2.5m) | ($3.3m) | ($4.9m) | $18.6m | ($173.0m) | $295.2m | ($190.1m) | |
| Interest | $460.8m | $0 | $555.4m | $684.8m | $642.5m | $611.6m | $561.1m | $492.6m | |
| Net cash provided by operating activities | $2.3b | $0 | $1.2b | $3.0b | $3.0b | $2.8b | $2.3b | $2.3b | |
| Capital expenditures | ($252.1m) | ($213.2m) | ($243.0m) | ($457.2m) | ($406.0m) | ($377.0m) | ($326.0m) | ($378.8m) | |
| Proceeds from sale of property, plant and equipment | $0 | $0 | $2.1m | $18.3m | $13.8m | $14.0m | $2.7m | $34.9m | |
| Net cash (used in) provided by investing activities | ($1.2b) | $0 | ($301.1m) | ($117.8m) | $1.5b | ($764.1m) | $1.8b | ($427.7m) | |
| Proceeds from issuance of long-term debt | $2.6b | $7.4m | $983.3m | $1.7b | $1.9b | $300k | $0 | $0 | |
| Payments of long-term debt | ($3.2b) | ($1.1b) | ($2.5b) | ($4.2b) | ($3.7b) | ($1.3b) | ($3.7b) | ($100k) | |
| Issuance of common stock | — | — | $0 | $0 | $3.3m | $3.1m | $2.5m | $2.6m | |
| Cash dividends paid | ($600k) | $0 | $0 | ($399.0m) | ($581.6m) | ($575.6m) | ($574.8m) | ($561.2m) | |
| Net cash used in financing activities | ($1.1b) | $0 | ($605.7m) | ($3.0b) | ($3.9b) | ($2.3b) | ($4.3b) | ($1.3b) | |
| Effect on cash of changes in exchange rates | ($21.0m) | $0 | $33.8m | ($30.9m) | ($38.9m) | ($2.5m) | ($30.7m) | $17.6m | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $19.4m | $0 | $358.8m | ($143.8m) | $556.3m | ($268.9m) | ($257.5m) | $611.9m | |
| Cash, cash equivalents and restricted cash — beginning of period | $389.3m | $0 | $850.0m | $706.2m | $1.3b | $993.6m | $736.1m | $1.3b | |
| Taxes paid related to net share settlement of equity awards | ($10.1m) | ($8.4m) | ($7.9m) | ($17.4m) | ($17.3m) | ($38.2m) | ($53.3m) | ($30.2m) |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.